MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
$123,294K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Issuance of common stock-Public ...
Maturities and sales of investme...
Net income (loss)
Others
Negative Cash Flow Breakdown
Purchases of investments
Operating lease liabilities
Other assets
Purchases of long-lived assets
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-
-
-437,987
-
Net income (loss)
80,080
269,369
-
-163,141
Depreciation and amortization
2,802
2,811
2,898
2,998
Amortization of premiums on investments, net
-322
-394
-1,549
-1,315
Noncash lease expense
1,369
1,338
1,325
1,297
Change in fair value of equity investments
1,723
170
2,606
-1,335
Change in estimated fair value of contingent consideration
1,130
-890
-80
560
Payment of contingent consideration in excess of acquisition date fair value
0
-
0
0
Stock-based compensation
12,391
12,087
11,206
11,356
In-process research and development impairment
-
-
0
0
Non-cash restructuring, long-lived assets impairment and related charges
0
-
255
0
Other non-cash items, net
41
82
132
40
Prepaid expenses and other current assets
-5,677
-382
8,077
-4,215
Other assets
604
-657
8,718
2,792
Accounts payable
12,309
-4,226
2,955
-5,402
Accrued liabilities and other liabilities
8,392
-17,223
10,104
-14,155
Operating lease liabilities
-2,306
-2,273
-2,323
-1,792
Deferred revenue
-
-
-
-675
Net cash used in operating activities
123,326
-132,386
-25,876
-167,570
Proceeds from sale of equipment
0
0
-110
37
Purchases of long-lived assets
32
390
348
317
Purchases of investments
352,099
158,374
255,822
264,447
Maturities and sales of investments
154,989
170,599
342,931
305,173
Net cash (used in) provided by investing activities
-197,142
11,835
86,651
40,446
Proceeds from exercise of stock options
1,440
174
1
101
Proceeds from issuance of common stock under espp
1,356
-
1,040
0
Issuance of common stock-Public Offering
162,205
-
-
-
Issuance of common stock-Astellas Pharma Inc.
75,724
-
-
-
Issuance of common stock in connection with a follow-on public offering, net of issuance cost
-
162,349
-
-
Other financing activities
0
-
-2
1
Net cash provided by financing activities
78,376
162,523
1,039
102
Net increase (decrease) in cash, cash equivalents and restricted cash and cash equivalents
4,560
41,972
61,814
-127,022
Cash, cash equivalents and restricted cash and cash equivalents at beginning of period
283,042
241,070
179,256
318,695
Cash, cash equivalents and restricted cash and cash equivalents at end of period
287,602
-
-
-
Obtaining a right-of-use asset in exchange for a lease liability
0
-
-
-
Cash and cash equivalents
278,729
-
-
-
Restricted cash and cash equivalents, current
1,929
-
-
-
Restricted cash and cash equivalents, noncurrent
6,944
-
-
-
Total cash, cash equivalents and restricted cash and cash equivalents
287,602
283,042
241,070
179,256
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net income (loss)
$80,080K
(134.53%↑ Y/Y)
Stock-based compensation
$12,391K
(-53.26%↓ Y/Y)
Accounts payable
$12,309K
(65.35%↑ Y/Y)
Accrued liabilities and
other liabilities
$8,392K
(253.76%↑ Y/Y)
Prepaid expenses and
other current assets
-$5,677K
(4.38%↑ Y/Y)
Depreciation and
amortization
$2,802K
(-51.56%↓ Y/Y)
Change in fair value of
equity investments
$1,723K
(157.43%↑ Y/Y)
Issuance of common
stock-Public Offering
$162,205K
Noncash lease expense
$1,369K
(-41.94%↓ Y/Y)
Change in estimated
fair value of...
$1,130K
(-89.74%↓ Y/Y)
Amortization of premiums on
investments, net
-$322K
(95.13%↑ Y/Y)
Other non-cash items,
net
$41K
(-30.51%↓ Y/Y)
Issuance of common
stock-Astellas Pharma Inc.
$75,724K
Proceeds from exercise of
stock options
$1,440K
(15.48%↑ Y/Y)
Proceeds from issuance of
common stock under espp
$1,356K
(-22.82%↓ Y/Y)
Net cash used in
operating activities
$123,326K
(162.18%↑ Y/Y)
Net cash provided by
financing activities
$78,376K
(2864.30%↑ Y/Y)
Canceled cashflow
$2,910K
Canceled cashflow
$162,349K
Net increase
(decrease) in cash, cash...
$4,560K
(136.72%↑ Y/Y)
Canceled cashflow
$197,142K
Operating lease
liabilities
-$2,306K
(29.11%↑ Y/Y)
Other assets
$604K
(-46.64%↓ Y/Y)
Maturities and sales of
investments
$154,989K
(-71.98%↓ Y/Y)
something is missing
-$162,349K
Net cash (used in)
provided by investing...
-$197,142K
(-207.57%↓ Y/Y)
Canceled cashflow
$154,989K
Purchases of investments
$352,099K
(-3.82%↓ Y/Y)
Purchases of long-lived
assets
$32K
(-99.23%↓ Y/Y)
Buy us a coffee
Vir Biotechnology, Inc. (VIR)
Vir Biotechnology, Inc. (VIR)